All Brandee Pappalardo articles
-
NewsJ&J’s Tremfya secures two paediatric psoriasis approvals from FDA
The US FDA approvals make the drug the first IL-23 inhibitor to be licensed for two common skin conditions.
The US FDA approvals make the drug the first IL-23 inhibitor to be licensed for two common skin conditions.